Abbvie has backed out of a development program inked in June 2015 using Halozyme Therapeutics’ ENHANZE™ platform technology and a tumor necrosis factor-alpha (TNF-alpha) target after target results were not achieved in a Phase I study. The companies will continue to work together to identify additional targets for co-development.

Under the terms of the original agreement, Halozyme received an initial $23 million payment and milestone payments totaling approximately $130 million for each of up to nine collaboration targets that were proposed. TNF-alpha was the first nominated target of the nine included as part of the agreement.

In addition to its proprietary product portfolio, Halozyme has partnerships with Roche, Baxalta, Pfizer, Janssen, and Lilly for its ENHANZE™ drug delivery platform. ENHANZE is based on Halozyme’s recombinant human hyaluronidase enzyme, which has been shown to remove traditional limitations on the volume of biologics that can be delivered subcutaneously.

Previous articleAcorda Discontinues Dalfampridine for Post-Stroke Walking Difficulties
Next articleNovartis Acquires Selexys Pharmaceuticals